Stay updated on Long-Term Safety of KarXT in Alzheimer's Psychosis Clinical Trial
Sign up to get notified when there's something new on the Long-Term Safety of KarXT in Alzheimer's Psychosis Clinical Trial page.

Latest updates to the Long-Term Safety of KarXT in Alzheimer's Psychosis Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedNo significant updates to the study details are visible between the screenshots; enrollment figures, locations, eligibility criteria, and outcomes appear unchanged (any differences are visual). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check18 days agoChange DetectedExpanded the study’s location list and recruitment status details (new cities and institutions; some previous sites removed), resulting in a larger, more current set of locations and statuses.SummaryDifference4%

- Check33 days agoChange DetectedMajor expansion and refresh of trial locations and statuses (notably more sites and some Recruiting statuses) with updated contacts; several old site entries and locations were removed.SummaryDifference6%

- Check40 days agoChange DetectedUpgrade to v3.1.0 with a large addition of contact phone numbers; previous version v3.0.2 is removed.SummaryDifference0.0%

- Check54 days agoChange DetectedADEPT-3 now includes both KarXT and KarXT + KarX-EC arms; the KarXT-only entry is removed, and new identifiers, last update date, revision version, and site/contact information are added.SummaryDifference3%

- Check61 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content, names, pricing, or availability.SummaryDifference0.1%

Stay in the know with updates to Long-Term Safety of KarXT in Alzheimer's Psychosis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Long-Term Safety of KarXT in Alzheimer's Psychosis Clinical Trial page.